Loading
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Latest quote
$20.87
−$0.19 · -0.90%
After-hours
$20.40
−$0.47 · -2.25%
Oct 8, 7:38 PM ET
Regular session · ET · Market data may be delayed.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Day range
Current $20.87
52-week range
Current $20.87
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
100
Deep Value
Sentiment
80
Bullish
Risk
24
Moderate Risk
Momentum
48
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Day range
Current $20.87
52-week range
Current $20.87
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 425.13M USD | 358.71M USD | 310.46M USD | 331.34M USD | 391.87M USD |
| Cost of goods sold | 117.61M USD | 36.6M USD | 42.64M USD | 13.79M USD | — |
| Gross profit | 307.52M USD | 322.11M USD | 267.82M USD | 317.55M USD | 391.87M USD |
| Research and development | 30.6M USD | 13.65M USD | 33.92M USD | 41.43M USD | 576K USD |
| Selling, general, and administrative | 113.17M USD | 115.69M USD | 98.23M USD | 63.54M USD | 16.19M USD |
| Operating expenses | 143.77M USD | 155.25M USD | 153.94M USD | 110.55M USD | 16.76M USD |
| Interest income | 21.09M USD | 19.14M USD | 15.82M USD | 6.37M USD | 1.84M USD |
| Interest expense | 16.7M USD | 22.21M USD | 19.16M USD | 15.79M USD | 19.07M USD |
| Depreciation and amortization | 40.23M USD | 39.85M USD | 35.71M USD | 19.51M USD | 13.83M USD |
| Operating income | 163.75M USD | 166.87M USD | 113.89M USD | 207M USD | 375.1M USD |
| Net income | 271.17M USD | 23.39M USD | 179.72M USD | 213.92M USD | 265.85M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$38.00
82.08% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Sep 8, 2015 | $0.25Quarterly | Sep 10, 2015 | Sep 30, 2015 |
Dividend | Jun 10, 2015 | $0.25Quarterly | Jun 12, 2015 | Jun 30, 2015 |
Dividend | Mar 10, 2015 | $0.25Quarterly | Mar 12, 2015 | Mar 31, 2015 |
Dividend | Nov 21, 2014 | $0.25Quarterly | Nov 25, 2014 | Dec 23, 2014 |
Dividend | Aug 26, 2014 | $0.25Quarterly | Aug 28, 2014 | Sep 18, 2014 |
Ex-dividend Sep 8, 2015
$0.25
Quarterly
Record Sep 10, 2015 · Payment Sep 30, 2015
Ex-dividend Jun 10, 2015
$0.25
Quarterly
Record Jun 12, 2015 · Payment Jun 30, 2015
Ex-dividend Mar 10, 2015
$0.25
Quarterly
Record Mar 12, 2015 · Payment Mar 31, 2015
Ex-dividend Nov 21, 2014
$0.25
Quarterly
Record Nov 25, 2014 · Payment Dec 23, 2014
Ex-dividend Aug 26, 2014
$0.25
Quarterly
Record Aug 28, 2014 · Payment Sep 18, 2014
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR90.95M0.09%104.29B USD0.06%$137.31+0.17%
Vanguard Morningstar Total Stock Market ETFVTI46.35M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM41.76M0.05%78.56B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap ETFVB33.43M0.02%185.3B USD0.03%$287.63+0.23%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV30.22M0.11%26.69B USD0.33%$38.10+0.82%
Dimensional - US Targeted Value ETFDFAT22.29M0.07%30B USD0.33%$67.56+0.72%
Vanguard Morningstar Small-Cap Value ETFVBR21.28M0.03%68.2B USD0.05%$233.91+0.75%
Invesco Pharmaceuticals ETFPJP17.59M3.23%542.27M USD0.58%$120.96-0.47%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBU.S. Small Cap Value Portfolio ETF Class SharesDFSVDimensional - US Targeted Value ETFDFATVanguard Morningstar Small-Cap Value ETFVBRInvesco Pharmaceuticals ETFPJPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
